Skip to main content
SpringerLink
Log in

Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study

  • Guest editor's introduction
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

In a retrospective study of 319 primary breast cancers, we show that an immunoenzymatic assay of a solubilized fraction of EGF receptors indicates a prognostic value for EGFR which is in contradiction with some (but not all) other studies. It appears that different methodological approaches of measuring EGFR are not equivalent in terms of prognostic power. We emphasize the need for rigorous multicentric standardization and quality control of assays, followed by multistep validation of parameters oriented towards clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Foekens JA, Peters HA, Portengen H, Noordegraaf E, Berns EM, Klijn JG: Cell biological prognostic factors in breast cancer: a review. J Clin Immunoassay 14: 184–192, 1991

    Google Scholar 

  2. Perez R, Pascual M, Macias A, Lage A: Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 4:189–193, 1984

    Google Scholar 

  3. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398–1402, 1987

    Google Scholar 

  4. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelénat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989

    Google Scholar 

  5. Klijn JG, Berns PM, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3–17, 1992

    Google Scholar 

  6. McGuire WL: Breast cancer prognostic factors: evaluation guidelines [editorial comment]. J Natl Cancer Inst 83:154–155, 1991

    Google Scholar 

  7. EORTC Breast Cancer Cooperative Group: Revision of standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16:1513–1515, 1980

    Google Scholar 

  8. Blankenstein MA, Benraad TJ: Multilaboratory assessment of tissue prognostic factors in breast cancer: The EORTC Receptor Study Group Experience. Tonkin KS, Smith AM (eds) Breast Cancer 1992. Rodar Publishing, Montreal, 1992

    Google Scholar 

  9. Grimaux M, Mady E, Remvikos Y, Lainé-Bidron C, Magdelénat H: A simplified immunoenzymetric assay of the epidermal growth factor receptor in breast tumors: evaluation in 282 cases. Int J Cancer 45:255–262, 1990

    Google Scholar 

  10. Halpern J: Maximally selected chi-square statistics for small samples. Biometrics 38:1017–1023, 1982

    Google Scholar 

  11. Peto R, Pike MC, Armitage P: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39, 1977

    Google Scholar 

  12. Cox DR: Regression models and life tables. J R Stat Soc 34:187–220, 1972

    Google Scholar 

  13. Lansen B, Schumacher M: Maximally selected rank statistics. Biometrics 48:73–85, 1992

    Google Scholar 

  14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170, 1966

    Google Scholar 

  15. Miller R, Siegmund D: Maximally selected chi-square statistics. Biometrics 38:1011–1016, 1982

    Google Scholar 

  16. Koziol JA: On maximally selected chi-square statistics. Biometrics 47:1557–1561, 1991

    Google Scholar 

  17. Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83–89, 1990

    Google Scholar 

  18. Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr): results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150, 1991

    Google Scholar 

  19. Nicholson S, Sainsbury JRC, Needham GK, Chambers P, Farndon JR, Harris AL: Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer 42:36–41, 1988

    Google Scholar 

  20. Delarue JC, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173–178, 1988

    Google Scholar 

  21. Battaglia F, Scambia G, Rossi S, Panici PB, Bellantone R, Polizi G, Querzoli P, Negrini R, Iacobelli S, Crucitti F, Mancuso S: Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol 24:1685–1690, 1988

    Google Scholar 

  22. Koenders PG, Beex L, Geurts-Moespot A, Heuvel JT, Kienhuis C, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 51:4544–4548, 1991

    Google Scholar 

  23. Zeillinger R, Kury F, Speiser P, Sliutz G, Czerwenka K, Kubista E: EGFR and steroid receptors in breast cancer: A comparison with tumor grading, tumor size, lymph node involvement, and age. Clin Biochem 26:221–227, 1993

    Google Scholar 

  24. Foekens JA, Portengen H, Van Putten WLJ, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989

    Google Scholar 

  25. Dazzi H, Hasleton PS, Thatcher N, Barnes DM, Wilkes S, Swindell R, Lawson RAM: Expression of epidermal growth factor receptor (EGF-R) in non small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746–749, 1989

    Google Scholar 

  26. Pavon-Djavid G, Trouvat V, Correia J, Serne H, Magdelénat H, Josefowicz M: Quantitative solubilization of epidermal growth factor receptor (EGFR) from cell cultures for ELISA. Submitted (Ph D thesis available)

  27. Falette N, Lefebvre MF, Meggouh F, Eynard M, Garin E, Saez S: Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies. Breast Cancer Res Treat 20:177–183, 1991

    Google Scholar 

  28. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: Identification of a high-affinity receptor for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80:1337–1341, 1983

    Google Scholar 

  29. Kwok TT, Sutherland RM: Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer 49:73–76, 1991

    Google Scholar 

  30. Nicholson S, Sainsbury JRC, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–184, 1989

    Google Scholar 

  31. Koenders PG, Faverly D, Beex LVAM, Bruggink EDM, Kienhuis CBM, Benraad TJ: Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology. Eur J Cancer 28:693–697, 1992

    Google Scholar 

  32. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327–1333, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Biologie Tissulaire, Centre René Huguenin, 35 rue Dailly, 92211, St-Cloud, France

    F. Spyratos, K. Hacène, C. Andrieu & J. L. Floiras

  2. Assistance Publique de Marseille, France

    P. M. Martin & S. Romain

  3. Institut Curie, 26 rue d'Ulm, 75005, Paris, France

    H. Magdelénat

Authors
  1. F. Spyratos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. M. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Hacène
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Andrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Romain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. L. Floiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Magdelénat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spyratos, F., Martin, P.M., Hacène, K. et al. Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study. Breast Cancer Res Tr 29, 85–95 (1994). https://doi.org/10.1007/BF00666184

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666184

Key words

Search

Navigation